Título del Proyecto	**Identification of novel modulators of chronic inflammation in prevalent diseases: unveiling divergent mechanisms of disease (INFLAMES)**
Nº de expediente asignado	PIE14/00045
Abstract	We have recently learnt the importance of inflammation in prevalent diseases such as type 2 diabetes (T2D), obesity, and Crohn's disease (CD). However, little is known about the specific triggers of Inflammation, and the precise tissue-specific mechanisms that induce effectors and lead to cellular responses. Changes in the gut microbiota composition and function have been identified in chronic inflammatory conditions such as obesity/T2D and CD. Most of these changes are common to both conditions, and characterized by loss of microbial diversity and reduced butyrate production. In spite of the common alterations in microbiota, obese/T2D and CD patients show major differences in the inflammatory profile and on glucose homeostasis. The overall objective of this proposal is to identify the mechanistic basis for the distinct inflammatory profile in obese/T2D and CD patients, and to obtain proof of concept to enable novel therapeutic approaches. Our hypothesis is that the gut and mesenteric adipose tissue play a key role in the different inflammatory response between obese/T2D and CD patients. We propose two main specific objectives to be performed by a combination of clinical and epidemiological strategies and using appropriate cellular and animal models: 1) Identification of disease mechanisms by extensive study of the metabolic, inflammatory, and gut mucosal status in obese, T2D and CD patients. The findings will be validated in two large cohorts (EPIC and PREDIMED). 2) Analysis of the metabolic and inflammatory properties of mesenteric fat will be studied in obese, T2D and CD patients as well as in animal models of those diseases. Target validation will be also performed by using appropriate cell models.

	This consortium aims to provide new information of use for a better care of obese, T2D and CD patients. In addition, we will set the stage for the discovery of novel drug targets for the treatment of chronic inflammatory disorders.
Entidad Financiadora	Instituto de Salud Carlos III
Convocatoria:	Proyectos Integrados de Excelencia – Convocatoria AES2014
Importe de la ayuda	679.800€
Fechas de ejecución del proyecto	01/01/2015-30/06/2018
	Estas ayudas están financiadas por el Instituto de Salud Carlos III y cofinanciadas por el FEDER, Programa Operativo Crecimiento Inteligente 2014-2020 “Una manera de hacer Europa”
	
Enlaces:	http://www.ciberisciii.es/areas-tematicas/grupo-de-investigacion?id=69